Investigation of Serum Endocan Levels in Diabetic Peripheral Artery Patients

Background: Endocan, also known as specific molecule-1 in endothelial cell, plays an important role in endothelial dysfunction and inflammatory reaction [1, 2]. Serum endocan, a new biochemical marker of endothelial dysfunction, plays a role in the development of cardiovascular disease (CVD). In this study, we investigate there was a difference in serum endocan, CYP2R1, and Haptoglobin protein levels between patients with DM (+) PAH and those with DM (-) PAH. 
Methods: 55 volunteer patients who were diagnosed with DM (-) PAH and 24 volunteer patients who came to the same polyclinic and were diagnosed with only DM (+) PAH as a result of the examination were included. Endocan, Haptoglobulin and 25-hydroxylase (CYP2R1) measurements were made with the quantitative Enzyme linked immunosorbent analysis kit.
Results: Serum haptoglobulin levels were 1877.01±564.67 (g/L) in the group with DM (-) PAH, 1745.94±612.59 (g/L) in the group with DM (+) PAH, 25-hydroxylase (CYP2R1) levels were 51.41 (2.53-2722.18) (ng/ml) in the group with DM (-) PAH and 25.36 (9.43-624.57) (ng) in the group with DM (+) PAH. /ml) was detected. Serum endocan levels are: 157.95 (29.16-7026.64) (pg/ml) in the group with DM (-) PAH, and 586.23 (138.79- 3876.51) (pg/ml) in the group with DM (+) PAH was detected.
Conclusion: We compared serum endocan levels in patients with DM(+) PAH and DM(-)PAH, and we found that there was a significant difference (p<0.001 ). We found that serum endocan levels were significantly higher in patients diagnosed with DM(+) PAH compared to the other group.